The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2015

Filed:

Jul. 24, 2012
Applicants:

Abdellah Benjahad, Champigny sur Marne, FR;

Alain Moussy, Paris, FR;

Emmanuel Chevenier, Les Ulis, FR;

Willy Picoul, Lyons, FR;

Anne Lermet, Paris, FR;

Didier Pez, Nievroz, FR;

Jason Martin, Fresnes, FR;

Franck Sandrinelli, Balan, FR;

Inventors:

Abdellah Benjahad, Champigny sur Marne, FR;

Alain Moussy, Paris, FR;

Emmanuel Chevenier, Les Ulis, FR;

Willy Picoul, Lyons, FR;

Anne Lermet, Paris, FR;

Didier Pez, Nievroz, FR;

Jason Martin, Fresnes, FR;

Franck Sandrinelli, Balan, FR;

Assignee:

AB SCIENCE, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01); A61K 31/535 (2006.01); A61K 31/42 (2006.01); A61K 31/445 (2006.01); A61K 31/497 (2006.01); A61K 31/505 (2006.01); A61K 31/422 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/422 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 417/10 (2013.01); C07D 417/14 (2013.01);
Abstract

The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof: wherein R, R, R, A, Q, W and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.


Find Patent Forward Citations

Loading…